ホルモン不応性前立腺癌(HRPCA)の世界市場：インサイト・予測

• 英文タイトル：Global Hormone Refractory Prostate Cancer (HRPCA) Market Insights, Forecast to 2025

• レポートコード：QYR9ST02904 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

※本調査レポートでは、世界のホルモン不応性前立腺癌(HRPCA)市場について調査・分析し、以下の構成でお届け致します。ホルモン不応性前立腺癌(HRPCA)の種類別には、化学療法、ホルモン療法、免疫療法、放射線療法、手術に、用途別には、病院、外来手術センター、専門クリニックに、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別ホルモン不応性前立腺癌(HRPCA)売上データ ・地域別ホルモン不応性前立腺癌(HRPCA)市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別ホルモン不応性前立腺癌(HRPCA)市場規模：化学療法、ホルモン療法、免疫療法、放射線療法、手術 ・用途別ホルモン不応性前立腺癌(HRPCA)市場規模：病院、外来手術センター、専門クリニック ・主要メーカーの企業情報：Astellas Inc、Sanofi S.A、Dendreon Corporation, Bayer AG、Johnson & Johnson ・ホルモン不応性前立腺癌(HRPCA)の市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ...

Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.The global Hormone Refractory Prostate Cancer (HRPCA) market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hormone Refractory Prostate Cancer (HRPCA) market based on company, product type, end user and key regions.

This report studies the global market size of Hormone Refractory Prostate Cancer (HRPCA) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hormone Refractory Prostate Cancer (HRPCA) in these regions.
This research report categorizes the global Hormone Refractory Prostate Cancer (HRPCA) market by top players/brands, region, type and end user. This report also studies the global Hormone Refractory Prostate Cancer (HRPCA) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson

Market size by Product
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery
Market size by End User
Hospitals
Ambulatory Surgical Centers
Specialty Clinics

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Hormone Refractory Prostate Cancer (HRPCA) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hormone Refractory Prostate Cancer (HRPCA) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hormone Refractory Prostate Cancer (HRPCA) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hormone Refractory Prostate Cancer (HRPCA) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Hormone Refractory Prostate Cancer (HRPCA) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hormone Refractory Prostate Cancer (HRPCA) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

レポート目次

---

Table of Contents

1 Study Coverage
1.1 Hormone Refractory Prostate Cancer (HRPCA) Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Product
1.4.2 Chemotherapy
1.4.3 Hormonal Therapy
1.4.4 Immunotherapy
1.4.5 Radiation Therapy
1.4.6 Surgery
1.5 Market by End User
1.5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by End User
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Specialty Clinics
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size
2.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue 2014-2025
2.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales 2014-2025
2.2 Hormone Refractory Prostate Cancer (HRPCA) Growth Rate by Regions
2.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Regions
2.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Hormone Refractory Prostate Cancer (HRPCA) Sales by Manufacturers
3.1.1 Hormone Refractory Prostate Cancer (HRPCA) Sales by Manufacturers
3.1.2 Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Manufacturers
3.1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio (CR5 and HHI)
3.2 Hormone Refractory Prostate Cancer (HRPCA) Revenue by Manufacturers
3.2.1 Hormone Refractory Prostate Cancer (HRPCA) Revenue by Manufacturers (2014-2019)
3.2.2 Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Manufacturers (2014-2019)
3.3 Hormone Refractory Prostate Cancer (HRPCA) Price by Manufacturers
3.4 Hormone Refractory Prostate Cancer (HRPCA) Manufacturing Base Distribution, Product Types
3.4.1 Hormone Refractory Prostate Cancer (HRPCA) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hormone Refractory Prostate Cancer (HRPCA) Product Type
3.4.3 Date of International Manufacturers Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Product
4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Product
4.3 Hormone Refractory Prostate Cancer (HRPCA) Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by End User

6 North America
6.1 North America Hormone Refractory Prostate Cancer (HRPCA) by Countries
6.1.1 North America Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries
6.1.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Hormone Refractory Prostate Cancer (HRPCA) by Product
6.3 North America Hormone Refractory Prostate Cancer (HRPCA) by End User

7 Europe
7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) by Countries
7.1.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries
7.1.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) by Product
7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) by End User

8 Asia Pacific
8.1 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) by Countries
8.1.1 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries
8.1.2 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) by Product
8.3 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) by End User

9 Central & South America
9.1 Central & South America Hormone Refractory Prostate Cancer (HRPCA) by Countries
9.1.1 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries
9.1.2 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Hormone Refractory Prostate Cancer (HRPCA) by Product
9.3 Central & South America Hormone Refractory Prostate Cancer (HRPCA) by End User

10 Middle East and Africa
10.1 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) by Countries
10.1.1 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries
10.1.2 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) by Product
10.3 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) by End User

11 Company Profiles
11.1 Astellas Inc
11.1.1 Astellas Inc Company Details
11.1.2 Company Business Overview
11.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Products Offered
11.1.5 Astellas Inc Recent Development
11.2 Sanofi S.A
11.2.1 Sanofi S.A Company Details
11.2.2 Company Business Overview
11.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Products Offered
11.2.5 Sanofi S.A Recent Development
11.3 Dendreon Corporation, Bayer AG
11.3.1 Dendreon Corporation, Bayer AG Company Details
11.3.2 Company Business Overview
11.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Products Offered
11.3.5 Dendreon Corporation, Bayer AG Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Company Business Overview
11.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Products Offered
11.4.5 Johnson & Johnson Recent Development

12 Future Forecast
12.1 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Regions
12.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Regions 2019-2025
12.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Regions 2019-2025
12.2 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Product
12.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Product 2019-2025
12.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Product 2019-2025
12.3 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by End User
12.4 North America Hormone Refractory Prostate Cancer (HRPCA) Forecast
12.5 Europe Hormone Refractory Prostate Cancer (HRPCA) Forecast
12.6 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Forecast
12.7 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Forecast
12.8 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hormone Refractory Prostate Cancer (HRPCA) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables and Figures

Figure Hormone Refractory Prostate Cancer (HRPCA) Product Picture
Table Hormone Refractory Prostate Cancer (HRPCA) Market Segments
Table Key Manufacturers Hormone Refractory Prostate Cancer (HRPCA) Covered
Table Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Product 2019-2025 (K Units) & (Million US$)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Product 2014-2025
Figure Chemotherapy Product Picture
Table Major Manufacturers of Chemotherapy
Figure Hormonal Therapy Product Picture
Table Major Manufacturers of Hormonal Therapy
Figure Immunotherapy Product Picture
Table Major Manufacturers of Immunotherapy
Figure Radiation Therapy Product Picture
Table Major Manufacturers of Radiation Therapy
Figure Surgery Product Picture
Table Major Manufacturers of Surgery
Table Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by End User 2019-2025 (K Units)
Figure Hospitals
Figure Ambulatory Surgical Centers
Figure Specialty Clinics
Figure Hormone Refractory Prostate Cancer (HRPCA) Report Years Considered
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Market Size 2014-2025 (Million US$)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales 2014-2025 (K Units)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions 2014-2019 (K Units) & (Million US$)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Regions 2014-2019 (K Units)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Regions 2014-2019
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Regions 2014-2019
Figure 2018 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Regions
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Regions 2014-2019 (Million US$)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Regions 2014-2019
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Regions 2014-2019
Figure 2018 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Regions
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Manufacturers (2014-2019) (K Units)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Share by Manufacturers (2014-2019)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Hormone Refractory Prostate Cancer (HRPCA) Revenue by Manufacturers (2014-2019) (Million USD)
Table Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Manufacturers (2014-2019)
Figure Hormone Refractory Prostate Cancer (HRPCA) Value Share by Manufacturers in 2018
Table Key Manufacturers Hormone Refractory Prostate Cancer (HRPCA) Price (2014-2019) (USD/Unit)
Table Hormone Refractory Prostate Cancer (HRPCA) Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Hormone Refractory Prostate Cancer (HRPCA) Product Type
Table Date of International Manufacturers Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Product (2014-2019) (K Units)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Share by Product (2014-2019)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Product (2014-2019)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Product in 2018
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Product (2014-2019) (Million US$)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Product (2014-2019)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Product (2014-2019)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Product in 2018
Table Hormone Refractory Prostate Cancer (HRPCA) Price by Product 2014-2019 (USD/Unit)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales by End User (2014-2019) (K Units)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Share by End User (2014-2019)
Figure Global Sales Hormone Refractory Prostate Cancer (HRPCA) Market Share by End User (2014-2019)
Figure Global Sales Hormone Refractory Prostate Cancer (HRPCA) Market Share by End User in 2018
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate 2014-2019 (K Units)
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate 2014-2019 (Million US$)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2014-2019) (K Units)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2014-2019)
Figure 2018 North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries
Table North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2014-2019) (Million US$)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2014-2019)
Figure 2018 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries
Figure United States Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure United States Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (K Units)
Figure Canada Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Canada Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Mexico Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Sales by Product (2014-2019) (K Units)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Product (2014-2019)
Figure 2018 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Product
Table North America Hormone Refractory Prostate Cancer (HRPCA) Sales by End User (2014-2019) (K Units)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by End User (2014-2019)
Figure 2018 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by End User
Figure Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate 2014-2019 (K Units)
Figure Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2014-2019) (K Units)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2014-2019)
Figure 2018 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2014-2019) (Million US$)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries
Figure Germany Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Germany Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure France Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure France Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure UK Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Italy Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Russia Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Sales by Product (2014-2019) (K Units)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Product (2014-2019)
Figure 2018 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Product
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Sales by End User (2014-2019) (K Units)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by End User (2014-2019)
Figure 2018 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by End User
Figure Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate 2014-2019 (K Units)
Figure Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2014-2019) (K Units)
Table Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries
Table Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries
Figure China Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure China Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Korea Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure India Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure India Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Australia Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Indonesia Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Malaysia Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Philippines Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Thailand Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Vietnam Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Singapore Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales by Product (2014-2019) (K Units)
Table Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Product
Table Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales by End User (2014-2019) (K Units)
Table Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by End User
Figure Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate 2014-2019 (K Units)
Figure Central & South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2014-2019) (K Units)
Table Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries
Table Central & South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2014-2019) (Million US$)
Table Central & South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries
Figure Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Brazil Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Argentina Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales by Product (2014-2019) (K Units)
Table Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Product
Table Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales by End User (2014-2019) (K Units)
Table Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Share by End User
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate 2014-2019 (K Units)
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2014-2019) (K Units)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries
Figure GCC Countries Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure GCC Countries Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Turkey Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure Egypt Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate (2014-2019) (K Units)
Figure South Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales by Product (2014-2019) (K Units)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Product
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales by End User (2014-2019) (K Units)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by End User
Table Astellas Inc Company Details
Table Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Astellas Inc Recent Development

Table Sanofi S.A Company Details
Table Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Sanofi S.A Recent Development

Table Dendreon Corporation, Bayer AG Company Details
Table Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Dendreon Corporation, Bayer AG Recent Development

Table Johnson & Johnson Company Details
Table Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Johnson & Johnson Recent Development

Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Regions 2019-2025 (K Units)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share Forecast by Regions 2019-2025
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share Forecast by Regions 2019-2025
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Product 2019-2025 (K Units)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share Forecast by Product 2019-2025
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Product 2019-2025 (Million US$)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share Forecast by Product 2019-2025
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by End User 2019-2025 (K Units)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share Forecast by End User 2019-2025
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate Forecast (2019-2025) (K Units)
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Central & South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Hormone Refractory Prostate Cancer (HRPCA) Value Chain
Table Hormone Refractory Prostate Cancer (HRPCA) Customers List
Table Hormone Refractory Prostate Cancer (HRPCA) Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

---